CD8A and lung carcinoma: A recent study has shown that pevonedistat may limit tumor infiltration by the immune suppressor cells, including tumor-associated macrophages and myeloid derived suppressor cells, and promote CD8+ T-cell infiltration in lung cancer models [41].